Checkmate 9ER: A New Arrow in Our Quiver

The results of Phase 3 Checkmate 9ER trial are in! The 9ER trial evaluated the combination of Nivolumab (“Nivo”) and Cabozantinib (“Cabo”). This trial compared the combo to Sunitinib (“Sutent”) in patients who had not previously been on a drug and who had disease that had spread or metastasized.

Nivo is an immunotherapy agent that helps your immune system recognize and mobilize your T-cells to attack the cancer cells. Cabo is a TKI (tyrosine kinase inhibition) drug. The combo improved progression free survival (PFS), meaning the cancer did not progress as quickly compared to the other drug. It also improved OS (overall survival) in patients previously untreated. There were 651 patients in the trial. Nivo and Cabo are each approved by the FDA. This new combo is not yet approved, but will likely be approved in the near future. Other good news is that patient’s toxicity to the drug combo and their quality of life was improved. As soon as this combination is approved, it will give patients another option in their arsenal to battle mRCC.

Read the 2020 ESMO News Release here.

WHO WE ARE →

WHAT WE DO →

OUR STORIES →

THE KIDNEY CANCER COMMUNITY →

SCIENTIFIC ADVISORS →

DONATE →

CONTACT →

Latest News

Chuck Stravin: “With Time Comes Hope”

Chuck Stravin: “With Time Comes Hope”

Chuck Stravin is married to his high school sweetheart, Liz, and lives in Quincy, Massachusetts, just south of Boston. Diagnosed with advanced renal cancer in 2015, Chuck is beating the odds and has become a passionate advocate for kidney cancer research funding.   For this month's Community...

SPRING ADVOCACY DAYS 2023 →

JOIN OUR COMMUNITY →

RAISING AWARENESS →

BE AN ADVOCATE →

DONATE NOW →

CONTACT →

Latest News

From the Heart to the Hill: Advocating for Kidney Cancer Research Funding

From the Heart to the Hill: Advocating for Kidney Cancer Research Funding

Spring Advocacy : By the Numbers KidneyCAN is thrilled to announce the success of our Spring Advocacy Days event, which took place on March 13th in person in Washington, D.C., and on March 14th virtually. We are grateful for the 186 confirmed meetings with representatives from 42 states, including...

Patient Resource Center

UNDERSTANDING YOUR KIDNEY CANCER DIAGNOSIS

BUILDING YOUR CARE TEAM

TREATMENT & TRIAL OPTIONS

LIVING WELL WITH KIDNEY CANCER

CLINICAL TRIALS →

IMMUNOTHERAPY →

KCRS: KIDNEY CANCER RESEARCH SUMMIT →

RESEARCH OPPORTUNITIES →

NEWS →

Latest News

From the Heart to the Hill: Advocating for Kidney Cancer Research Funding

From the Heart to the Hill: Advocating for Kidney Cancer Research Funding

Spring Advocacy : By the Numbers KidneyCAN is thrilled to announce the success of our Spring Advocacy Days event, which took place on March 13th in person in Washington, D.C., and on March 14th virtually. We are grateful for the 186 confirmed meetings with representatives from 42 states, including...

SUPPORT OUR WORK →

ROCK THE RUN 2023 →

FUNDRAISE FOR KIDNEYCAN →

DONATE →

CONTACT →

Latest News

Chuck Stravin: “With Time Comes Hope”

Chuck Stravin: “With Time Comes Hope”

Chuck Stravin is married to his high school sweetheart, Liz, and lives in Quincy, Massachusetts, just south of Boston. Diagnosed with advanced renal cancer in 2015, Chuck is beating the odds and has become a passionate advocate for kidney cancer research funding.   For this month's Community...